Inify Laboratories AB — Earnings Release 2025

Apr 30, 2025

Inify Laboratories: Continued strong growth - construction and establishment in the UK

Inify Laboratories: Continued strong growth - construction and establishment in the UK

STOCKHOLM - April 30, 2025 - Inify Laboratories, a unique laboratory service

that provides cancer diagnostics within pathology, continued to deliver sales

growth and positive margins in Sweden, alongside steady progress in its UK

expansion.

"We remain fully focused on growth in Sweden, our UK establishment, and further

development of our system for gastrointestinal diagnostics," says CEO Fredrik

Palm, CEO of Inify Laboratories.

Sales in the first quarter amounted to SEK 5.1 million (2.2), representing 130%

growth compared to the same period in 2024. Cash balance at the end of the

quarter amounted to SEK 151.1 million, strengthened by the SEK 150 million share

issue completed in February.

"Our laboratory operations continue to generate positive financial results, with

further improvement expected as sample volumes grow," says Palm.

During the first quarter, Inify established its initial UK organisation by

recruiting key personnel for subsidiary management, laboratory operations, and

sales. Planning for the laboratory construction is progressing well, and the

company has selecting a modern, newly built property in a business park just

south of Oxford.

"In parallel with the laboratory establishment, we have an ongoing, close

dialogue with public (NHS) and private healthcare providers - our future

customers," said Palm.

Together with its customers, Inify has begun developing new, structured

processes in prostate cancer diagnostics, delivering superior efficiency and

quality.

"We are one quarter into what promises to be a very exciting year. Inify is

growing in Sweden, expanding internationally, and at the same time developing

new capabilities to broaden our service offering into gastrointestinal

diagnostics. In short, we are at the forefront of setting a new standard," Palm

concludes.

For further information, please contact CEO Fredrik Palm,

fredrik.palm@inify.com, or visit https://www.inify.com

The future of pathology

Inify Laboratories provides cancer diagnostics through ultramodern laboratory

services within pathology. It uses a fully digital, standardised and AI

-supported workflow to optimise quality and response times, initially within

prostate cancer.The concept is scalable and can be extended to other diagnoses.

The service includes the whole chain of sample handling: from logistics, to

sample preparation, to reporting by a pathologist. The report is assisted by our

own AI, proven in clinical studies to have world-leading accuracy. The complete

workflow is supported by a tailor-made process control system.

The company, based in Sweden, became independent in 2022 through a spin-off

fromContextVision (https://www.contextvision.com/), with 40 years of experience

within digital imaging for medical applications. Its shares are listed

onEuronext Growth Oslo under the ticker

INIFY (https://live.euronext.com/en/product/equities/SE0017486103-MERK).